WALTHAM, Mass.– The U.S. Food and Drug Administration (FDA) has granted approval for Revvity Inc.’s Auto-Pure 2400 liquid handling platform in conjunction with the T-SPOT.TB test. This approval marks a significant advancement in the detection of latent tuberculosis (TB), providing laboratories with an efficient and reliable high-throughput diagnostic tool.
Originally launched outside the United States in 2024, the Auto-Pure 2400 system automates the T-SPOT.TB test, enabling laboratories to enhance productivity without sacrificing clinical accuracy. The approval is expected to support timely diagnosis and treatment of latent TB, aiding in global efforts to contain the infectious disease.
“The integration of the Auto-Pure 2400 platform with the T-SPOT.TB test gives laboratories the ability to process latent TB tests at higher volumes without compromising clinical accuracy,” said Yves Dubaquie, senior vice president of diagnostics at Revvity. “By automating T-SPOT.TB testing, we are empowering laboratories with increased throughput and reliability, ultimately leading to better patient outcomes.”
Revvity’s newly approved automated system is expected to bolster TB detection capabilities in U.S. laboratories while contributing to global efforts in controlling the disease through improved diagnostic efficiency and accuracy.
